AbbVie (ABBV) EBITDA Margin (2012 - 2026)

AbbVie has disclosed EBITDA Margin across 15 years of filings, most recently posting 26.6% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 138.0% year-over-year to 26.6%; the TTM figure through Mar 2026 stood at 24.41% (up 685.0% YoY), while the FY2025 annual figure was 24.65%, up 843.0% from the prior year.
• EBITDA Margin fell to 26.6% in Q1 2026, from 27.34% in the prior quarter.
• Over the last five years, EBITDA Margin for ABBV reached as high as 36.39% in Q4 2022 and fell as low as 9.87% in Q4 2024.
• The 5-year median for EBITDA Margin is 26.6% (2026), against an average of 24.21%.
• Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 3221 bps — and 2025, when it jumped 3721 bps.
• A 5-year view of EBITDA Margin shows it stood at 36.39% in 2022, then plunged by 39 bps to 22.34% in 2023, then tumbled by 144 bps to 9.87% in 2024, then surged by 377 bps to 27.34% in 2025, then decreased by 3 bps to 26.6% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 26.6%, 27.34%, and 12.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.